VRSK
22
11
AZO
53
4
KHC
54
7
TJX
53
3
GRMN
45
2
PXD
46
2
KMB
67
7
VLO
55
3
PNR
33
4
HCP
31
-5
BXP
18
3
GOOG
42
-2
DE
53
-3
CLX
68
4
KR
56
3
HRB
52
5
MMM
25
2
NEM
55
3
EW
59
17
T
35
5
VRSK
22
11
AZO
53
4
KHC
54
7
TJX
53
3
GRMN
45
2
PXD
46
2
KMB
67
7
VLO
55
3
PNR
33
4
HCP
31
-5
BXP
18
3
GOOG
42
-2
DE
53
-3
CLX
68
4
KR
56
3
HRB
52
5
MMM
25
2
NEM
55
3
EW
59
17
T
35
5
Financhill
Back

AstraZeneca PLC 10K Form

Buy
67

AZN
AstraZeneca PLC

Last Price:
67.92
Seasonality Move:
6.45%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AZN News And Ratings

See the #1 stock for the next 7 days that we like better than AZN

AZN Financial Statistics

Sales & Book Value

Annual Sales: $44.35B
Cash Flow: $1.84B
Price / Cash Flow: 29.28
Annual Sales: $11.95
Price / Book: 5.68

Profitability

EPS (TTM): 1.05500
Net Income (TTM): $3.29B
Gross Margin: $31.96B
Return on Equity: 8.95%
Return on Assets: 3.34%

AstraZeneca PLC Earnings Forecast

Key AstraZeneca PLC Financial Ratios

  • The Gross Profit Margin over the past 25 years for AZN is 72.06%.
  • The Selling, General & Administrative Expenses for AZN have been equal to 40.44% of Gross Profit Margin.
  • The Research & Development expenses have been 22.01% of Revenue.
  • The Interest Expense is 40.45% of Operating Income.
  • The Net Earning history of AZN is 7.41% of Total Revenues.
  • Per Share Earnings over the last 33 years have been positive in 19 years.

AstraZeneca PLC Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Drug Manufacturers - General
Sector: Healthcare
Current Symbol: AZN
CUSIP: 046353
Website: astrazeneca.com

Debt

Debt-to-Equity Ratio: 0.76
Current Ratio: 0.86
Quick Ratio: 0.61

Price-to-Earnings

Trailing P/E Ratio: 64.37
Forward P/E Ratio: 12.22

AZN Technical Analysis vs Fundamental Analysis

Buy
67
AstraZeneca PLC (AZN) is a Buy

Is AstraZeneca PLC a Buy or a Sell?

  • AstraZeneca PLC stock is rated a Buy
    The current AstraZeneca PLC [AZN] share price is $67.91. The Score for AZN is 67, which is 34% above its historic median score of 50, and infers lower risk than normal.